齐拉西酮联合奥氮平治疗难治性精神分裂症的效果及安全性

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect and safety of Ziprasidone combined with Olanzapine in the treatment of treatment-resistant (TRS).Methods A total of 72 TRS patients diagnosed at Zaozhuang Mental Health Center and Heze Third People′s Hospital from March 2018 to December 2019 were selected as the research objects.According to the random number table method, the patients were divided into the control group (Olanzapine treatment) and the observation group (Ziprasidone treatment based on the control group), with 36 cases in each group.Before treatment and after 3 months of treatment, the positive and negative symptom scale (PANSS) was performed to assess the severity of symptoms in patients, and the total effective rate was calculated based on the PANSS score.The Wechsler memory scale(WMS) and trail making test (TMT) were used to evaluate the patients′ cognitive function.The total incidence of adverse reactions was compared between the two groups.Results The total effective rate of treatment in the observation group (91.67%) was higher than that in the control group (72.22%), with statistically significant difference (P＜0.05).After treatment, the WMS scores of the two groups were higher than those before treatment, and the WMS score in the observation group was higher than that in the control group, with statistically significant differences (P＜0.05).The TMT scores of the two groups were lower than those before treatment, and the TMT score in the observation group was lower than that in the control group, with statistically significant differences (P＜0.05).The total incidence of adverse reactions such as salivation, dizziness, headache, drowsiness, constipation and epilepsy in the control group was 27.78%, and 19.44% in the observation group, there was no significant difference between the two groups (P＞0.05).Conclusion The combination of Ziprasidone and Olanzapine has a good effect in the treatment of TRS, which significantly improves the cognitive function of patients without increasing the total incidence of adverse reactions.

Key words： Treatment-resistant schizophrenia Ziprasidone Olanzapine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAO Bao-rui
	CHEN Jia-min
	MA Qing

Cite this article:

CAO Bao-rui,CHEN Jia-min,MA Qing. Effect and safety of Ziprasidone combined with Olanzapine in the treatment of treatment-resistant schizophrenia[J]. 中国当代医药, 2021, 28(10): 113-116.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I10/113

[1]	刘爽，庞羽，李刚.氯普噻吨联合氟哌啶醇治疗难治性精神分裂症的临床研究[J].现代药物与临床，2020，35（8）：1562-1565.
[2]	Rakitzi S，Georgila P.Integrated Psychological Therapy and Treatment-Resistant Schizophrenia：Initial Findings[J].Psychiatry，2019，82（4）：354-367.
[3]	沈文婧，高威，岳静，等.小剂量氨磺必利配合奥氮平对难治性精神分裂患者睡眠及认知功能影响研究[J].中国药师，2019，22（1）：102-105.
[4]	滕良峰，汪丽.齐拉西酮联合无抽搐电休克治疗难治性精神分裂症的临床效果[J].当代医学，2020，26（29）：156-157.
[5]	中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版（精神障碍分类）[J].中华精神科杂志，2001，34（3）：184-188.
[6]	Kane JM.Treatment-resistant schizophrenic patients[J].J Clin Psychiatry，1996，9（1）：35-40.
[7]	张艳.氯氮平联合氨磺必利对难治性精神分裂症患者PANSS、TESS 评分的影响[J].现代诊断与治疗，2020，31（3）：366-367.
[8]	吴兴曲，贾婷，禹晓东，等.氯氮平联合阿立哌唑治疗难治性精神分裂症的临床效果及对糖脂代谢和胰岛素抵抗的影响[J].解放军医药杂志，2019，31（10）：71-75.
[9]	Vanes LD，Mouchlianitis E，Collier T，et al.Differential neural reward mechanisms in treatment-responsive and treatment-resistant schizophrenia[J].Psychol Med，2018，48（14）：2418-2427.
[10]	刘宏明，王建，陈盛阳.四种药物治疗精神分裂症的疗效与经济学评价[J].中国医院用药评价与分析，2020，20（7）：821-823.
[11]	郎小娥，薛晓燕，侯鑫，等.低剂量齐拉西酮联合低剂量舍曲林治疗难治性精神分裂症的疗效和安全性研究[J].中西医结合心脑血管病杂志，2020，18（9）：1451-1456.
[12]	魏玲，龚飞中，熊生杰，等.齐拉西酮与奥氮平对女性精神分裂症患者阴、阳性症状与内分泌代谢的影响[J].国际精神病学杂志，2019，46（1）：106-108.
[13]	滕军波，吕斌军，牛凯.齐拉西酮联合奥氮平治疗难治性精神分裂症的效果及对患者认知功能、血清白蛋白、尿酸、总胆红素的影响[J].中国基层医药，2020，27（16）：2025-2027.
[14]	杨富菊.奥氮平与齐拉西酮对精神分裂症患者阳性与阴性症状量表、副反应量表评分及疗效的影响比较[J].实用临床医药杂志，2017，21（1）：156-158.
[15]	Boland X，Chhabra P.Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia：A Case Report[J].J Psychiatr Pract，2019，25（2）：135-138.
[16]	刘伟，雷雨.齐拉西酮联合六味地黄丸治疗老年精神分裂症的效果[J].中国老年学杂志，2020，40（8）：1691-1693.
[17]	曹峰，谢渭根.奥氮平与齐拉西酮治疗精神分裂症的疗效及对糖脂代谢的影响[J].中华全科医学，2020，18（2）：217-219.
[18]	宋新虹，贺守彬.齐拉西酮治疗奥氮平致体重增加精神分裂症患者的效果和安全性[J].中国当代医药，2019，26（1）：91-93，97.
[19]	付飞，陈汉波.奥氮平联合齐拉西酮对老年重度精神分裂症患者血清学指标和认知功能的影响探讨[J].中国医学创新，2019，16（24）：32-35.
[20]	朱桂东，宋清海，徐伟杰，等.齐拉西酮联合奥氮平对老年难治性精神分裂症患者症状及血清瘦素和脑源性神经营养因子水平的影响[J].中国慢性病预防与控制，2019，27（3）：219-222.